At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Stereotactic Radiation 10 Gy +2 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla
In Brief
A Phase 2 clinical trial evaluating Stereotactic Radiation 10 Gy, Stereotactic Radiation 12.5 Gy, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2011
Primary CompletionAug 2020
Study CompletionJun 2022
TodayJul 2026
First PostedApr 27, 2011
Enrollment StartApr 14, 2009
Primary CompletionAug 1, 2020
Study CompletionJun 1, 2022
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 15.2 years ago
Interventions
Stereotactic Radiation 10 Gyradiation
10 Gy three times over 10 days
Stereotactic Radiation 12.5 Gyradiation
12.5 Gy three times over 10 days
Stereotactic Radiation 15 Gyradiation
15 Gy three times over 10 days